Latest Products & Licence Changes

New drug - Toviaz

Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more

New drug - Tasigna

Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more

Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more

Once-daily ropinirole

Requip XL tablets (ropinirole prolonged release) offer a once-daily dosing schedule for the treatmen... Read more

Rimonabant psychiatric reactions

The MHRA has issued a drug safety update providing information on psychiatric adverse effects associ... Read more

New emollients launched

Two new liquid paraffin-based emollients Zerolatum emollient and Zerolatum Plus Emollient are availa... Read more

New drug - Pradaxa

Pradaxa (dabigatran etexilate) is the first oral direct thrombin inhibitor, indicated for the primar... Read more

New drug - Circadin

Lundbeck has launched Circadin (melatonin) for the short-term treatment of primary insomnia characte... Read more

Daktarin - increase in age

The minimum recommended age for use of Daktarin (miconazole) oral gel in infants has increased from ... Read more

New Tears Naturale available

Alcon has launched Tears Naturale Single Dose (hypromellose and dextran) preservative-free eye drops... Read more